Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Collegium Pharmaceutical (COLL) over the last 5 years, with Q3 2025 value amounting to $1.3 billion.

  • Collegium Pharmaceutical's Total Non-Current Liabilities fell 460.19% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year decrease of 460.19%. This contributed to the annual value of $1.4 billion for FY2024, which is N/A changed from last year.
  • Per Collegium Pharmaceutical's latest filing, its Total Non-Current Liabilities stood at $1.3 billion for Q3 2025, which was down 460.19% from $1.4 billion recorded in Q2 2025.
  • Collegium Pharmaceutical's Total Non-Current Liabilities' 5-year high stood at $1.4 billion during Q4 2024, with a 5-year trough of $1.3 billion in Q3 2025.